Nirvana Life Sciences Inc. (CSE: NIRV)
Canada
· Delayed Price · Currency is CAD
0.0750
0.00 (0.00%)
Nov 22, 2024, 4:00 PM EST
Nirvana Life Sciences Statistics
Total Valuation
Nirvana Life Sciences has a market cap or net worth of CAD 3.62 million. The enterprise value is 3.63 million.
Market Cap | 3.62M |
Enterprise Value | 3.63M |
Important Dates
The last earnings date was Monday, September 30, 2024.
Earnings Date | Sep 30, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Nirvana Life Sciences has 48.23 million shares outstanding. The number of shares has increased by 31.20% in one year.
Current Share Class | n/a |
Shares Outstanding | 48.23M |
Shares Change (YoY) | +31.20% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 20.37% |
Owned by Institutions (%) | n/a |
Float | 34.83M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.96 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
Current Ratio | 0.05 |
Quick Ratio | 0.02 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -139.00 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -197.82% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +150.00% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +150.00% |
50-Day Moving Average | 0.08 |
200-Day Moving Average | 0.04 |
Relative Strength Index (RSI) | 93.33 |
Average Volume (20 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -956,890 |
Pretax Income | -1.23M |
Net Income | -1.23M |
EBITDA | -921,770 |
EBIT | -956,890 |
Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 3,137 in cash and 23,624 in debt, giving a net cash position of -20,487 or -0.00 per share.
Cash & Cash Equivalents | 3,137 |
Total Debt | 23,624 |
Net Cash | -20,487 |
Net Cash Per Share | -0.00 |
Equity (Book Value) | -816,998 |
Book Value Per Share | -0.02 |
Working Capital | -979,789 |
Cash Flow
Operating Cash Flow | -252,662 |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Nirvana Life Sciences does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -31.20% |
Shareholder Yield | -31.20% |
Earnings Yield | -37.96% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |